PEGylated liposome containing sildenafil for the treatment of hypertension
Abstract
The purpose of this study was to prepare PEGylated liposomes containing sildenafil for the treatment of pulmonary arterial hypertension. PEGylated liposomes were prepared by thin film hydration method by varying the concentration of lipids. The prepared liposomes were characterized for the particle size, PDI, zeta potential, % entrapment efficiency and in-vitro release study. The optimized formulation exhibits a particle size of 104.27±1.4 nm, PDI of 0.449±0.02, zeta potential of -42.9±0.7 along with the maximum encapsulation of drug i.e. 87.30±2.6. Optimized formulation showed % cumulative drug release of 85.38±0.26 in 48 hr. From the study it can be concluded that the PEGylated liposomes containing sildenafil for the treatment of pulmonary arterial hypertension provides a sustained release of drug and further studies are required to confirm their efficacy at clinical level. Keywords: Sildenafil; PEGylated liposomes; Pulmonary arterial hypertension; % entrapment efficiency
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.